Beijing Tiantan Biological Products Corp Ltd (600161) — Strategic Asset Allocation Index
Beijing Tiantan Biological Products Corp Ltd (600161) has a Strategic Asset Allocation Index of 36.7% as of June 2023. Strategic assets (PP&E of CN¥4.42 Billion plus long-term investments of CN¥-) total CN¥4.42 Billion, measured against net assets of CN¥12.05 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Beijing Tiantan Biological Products Corp balance sheet independence to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Beijing Tiantan Biological Products Corp Ltd Strategic Asset Allocation Index (2000–2022)
This chart shows how Beijing Tiantan Biological Products Corp Ltd's Strategic Asset Allocation Index has evolved across 23 annual periods from 2000 to 2022. As of June 2023, the index stands at 36.7%, representing strategic assets of CN¥4.42 Billion against net assets of CN¥12.05 Billion CNY. For live market cap and overall valuation, see 600161 market cap overview.
Annual Strategic Asset Allocation Index for Beijing Tiantan Biological Products Corp Ltd (2000–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Beijing Tiantan Biological Products Corp Ltd from 2000 to 2022, covering 23 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See Beijing Tiantan Biological Products Corp shareholders equity for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 35.7% | CN¥4.05 Billion | CN¥4.05 Billion | CN¥- | CN¥11.36 Billion | ▲ +10.1 pp |
| 2021 | 25.6% | CN¥2.63 Billion | CN¥2.63 Billion | CN¥- | CN¥10.27 Billion | ▼ -7.5 pp |
| 2020 | 33.1% | CN¥2.00 Billion | CN¥2.00 Billion | CN¥- | CN¥6.03 Billion | ▲ +3.0 pp |
| 2019 | 30.1% | CN¥1.56 Billion | CN¥1.56 Billion | CN¥- | CN¥5.18 Billion | ▲ +5.5 pp |
| 2018 | 24.6% | CN¥1.07 Billion | CN¥986.87 Million | CN¥81.84 Million | CN¥4.35 Billion | ▼ -6.8 pp |
| 2017 | 31.4% | CN¥999.50 Million | CN¥922.12 Million | CN¥77.39 Million | CN¥3.18 Billion | ▼ -110.2 pp |
| 2016 | 141.6% | CN¥3.46 Billion | CN¥3.41 Billion | CN¥45.96 Million | CN¥2.44 Billion | ▼ -15.2 pp |
| 2015 | 156.8% | CN¥3.51 Billion | CN¥3.46 Billion | CN¥45.96 Million | CN¥2.24 Billion | ▲ +3.2 pp |
| 2014 | 153.6% | CN¥3.41 Billion | CN¥3.41 Billion | CN¥- | CN¥2.22 Billion | ▼ -2.8 pp |
| 2013 | 156.4% | CN¥3.40 Billion | CN¥3.40 Billion | CN¥- | CN¥2.18 Billion | ▼ -13.0 pp |
| 2012 | 169.4% | CN¥3.01 Billion | CN¥3.01 Billion | CN¥- | CN¥1.78 Billion | ▲ +50.3 pp |
| 2011 | 119.1% | CN¥1.72 Billion | CN¥1.72 Billion | CN¥- | CN¥1.45 Billion | ▲ +16.8 pp |
| 2010 | 102.2% | CN¥1.17 Billion | CN¥1.17 Billion | CN¥- | CN¥1.14 Billion | ▲ +6.6 pp |
| 2009 | 95.6% | CN¥907.43 Million | CN¥907.43 Million | CN¥- | CN¥949.13 Million | ▲ +35.9 pp |
| 2008 | 59.7% | CN¥451.99 Million | CN¥451.99 Million | CN¥- | CN¥756.97 Million | ▲ +4.4 pp |
| 2007 | 55.3% | CN¥401.41 Million | CN¥401.41 Million | CN¥- | CN¥725.57 Million | ▲ +3.2 pp |
| 2006 | 52.1% | CN¥369.08 Million | CN¥369.08 Million | CN¥- | CN¥708.35 Million | ▲ +6.4 pp |
| 2005 | 45.7% | CN¥305.84 Million | CN¥305.84 Million | CN¥- | CN¥669.09 Million | ▼ -2.0 pp |
| 2004 | 47.7% | CN¥303.56 Million | CN¥303.56 Million | CN¥- | CN¥636.79 Million | ▲ +5.3 pp |
| 2003 | 42.4% | CN¥254.17 Million | CN¥254.17 Million | CN¥- | CN¥599.70 Million | ▼ -34.8 pp |
| 2002 | 77.2% | CN¥223.01 Million | CN¥223.01 Million | CN¥- | CN¥289.04 Million | ▲ +4.5 pp |
| 2001 | 72.7% | CN¥210.55 Million | CN¥210.55 Million | CN¥- | CN¥289.68 Million | ▲ +5.3 pp |
| 2000 | 67.4% | CN¥188.08 Million | CN¥188.08 Million | CN¥- | CN¥279.21 Million | — |